+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Amyotrophic lateral sclerosis (ALS) - Market Insight, Epidemiology and Market Forecast -2032

  • ID: 4410579
  • Report
  • January 2022
  • Region: Global
  • 270 Pages
  • DelveInsight

FEATURED COMPANIES

  • AB Science
  • Amylyx Pharmaceuticals
  • Apellis Pharmaceuticals
  • Biogen
  • Eledon Pharmaceuticals
  • MediciNova
This "Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Amyotrophic lateral sclerosis (ALS), historical and forecasted epidemiology as well as the Amyotrophic lateral sclerosis (ALS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Amyotrophic lateral sclerosis (ALS) market report provides current treatment practices, emerging drugs, Amyotrophic lateral sclerosis (ALS) market share of the individual therapies, current and forecasted Amyotrophic lateral sclerosis (ALS) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Amyotrophic lateral sclerosis (ALS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019-2032

Amyotrophic lateral sclerosis (ALS) Disease Understanding and Treatment Algorithm


The Amyotrophic lateral sclerosis (ALS) market report gives a thorough understanding of the Amyotrophic lateral sclerosis (ALS) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis


This segment of the report covers the detailed diagnostic methods or tests for Amyotrophic lateral sclerosis (ALS).

Treatment


It covers the details of conventional and current medical therapies available in the Amyotrophic lateral sclerosis (ALS) market for the treatment of the condition. It also provides Amyotrophic lateral sclerosis (ALS) treatment algorithms and guidelines in the United States, Europe, and Japan.

Amyotrophic lateral sclerosis (ALS) Epidemiology


The Amyotrophic lateral sclerosis (ALS) epidemiology division provide insights about historical and current Amyotrophic lateral sclerosis (ALS) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings


The disease epidemiology covered in the report provides historical as well as forecasted Amyotrophic lateral sclerosis (ALS) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Amyotrophic lateral sclerosis (ALS) Epidemiology


The epidemiology segment also provides the Amyotrophic lateral sclerosis (ALS) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Amyotrophic lateral sclerosis (ALS) Drug Chapters


Drug chapter segment of the Amyotrophic lateral sclerosis (ALS) report encloses the detailed analysis of Amyotrophic lateral sclerosis (ALS) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Amyotrophic lateral sclerosis (ALS) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs


The report provides the details of the marketed product available for Amyotrophic lateral sclerosis (ALS) treatment.

Amyotrophic lateral sclerosis (ALS) Emerging Drugs


The report provides the details of the emerging therapies under the late and mid-stage of development for Amyotrophic lateral sclerosis (ALS) treatment.

Amyotrophic lateral sclerosis (ALS) Market Outlook


The Amyotrophic lateral sclerosis (ALS) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Amyotrophic lateral sclerosis (ALS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Amyotrophic lateral sclerosis (ALS) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Amyotrophic lateral sclerosis (ALS) market in 7MM is expected to change in the study period 2019-2032.

Key Findings


This section includes a glimpse of the Amyotrophic lateral sclerosis (ALS) market in 7MM.

The United States Market Outlook


This section provides the total Amyotrophic lateral sclerosis (ALS) market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook


The total Amyotrophic lateral sclerosis (ALS) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook


The total Amyotrophic lateral sclerosis (ALS) market size and market size by therapies in Japan is also mentioned.

Amyotrophic lateral sclerosis (ALS) Drugs Uptake


This section focusses on the rate of uptake of the potential drugs recently launched in the Amyotrophic lateral sclerosis (ALS) market or expected to get launched in the market during the study period 2019-2032. The analysis covers Amyotrophic lateral sclerosis (ALS) market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Amyotrophic lateral sclerosis (ALS) Pipeline Development Activities


The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Amyotrophic lateral sclerosis (ALS) key players involved in developing targeted therapeutics.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Amyotrophic lateral sclerosis (ALS) emerging therapies.

Reimbursement Scenario in Amyotrophic lateral sclerosis (ALS)


Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views


To keep up with current market trends, we take KOLs and SME's opinion working in Amyotrophic lateral sclerosis (ALS) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Amyotrophic lateral sclerosis (ALS) market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis


The publisher performs Competitive and Market Intelligence analysis of the Amyotrophic lateral sclerosis (ALS) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of Amyotrophic lateral sclerosis (ALS), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Amyotrophic lateral sclerosis (ALS) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Amyotrophic lateral sclerosis (ALS) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Amyotrophic lateral sclerosis (ALS) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Amyotrophic lateral sclerosis (ALS) market

Report Highlights

  • In the coming years, Amyotrophic lateral sclerosis (ALS) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Amyotrophic lateral sclerosis (ALS) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Amyotrophic lateral sclerosis (ALS). Launch of emerging therapies will significantly impact the Amyotrophic lateral sclerosis (ALS) market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Amyotrophic lateral sclerosis (ALS)
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Amyotrophic lateral sclerosis (ALS) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Amyotrophic lateral sclerosis (ALS) Pipeline Analysis
  • Amyotrophic lateral sclerosis (ALS) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Amyotrophic lateral sclerosis (ALS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Amyotrophic lateral sclerosis (ALS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Amyotrophic lateral sclerosis (ALS) Report Assessment


Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions Answered


Market Insights:

  • What was the Amyotrophic lateral sclerosis (ALS) market share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the Amyotrophic lateral sclerosis (ALS) total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Amyotrophic lateral sclerosis (ALS) market size during the forecast period (2019-2032)?
  • At what CAGR, the Amyotrophic lateral sclerosis (ALS) market is expected to grow in 7MM during the forecast period (2019-2032)?
  • What would be the Amyotrophic lateral sclerosis (ALS) market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the Amyotrophic lateral sclerosis (ALS) market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What is the disease risk, burden and unmet needs of the Amyotrophic lateral sclerosis (ALS)?
  • What is the historical Amyotrophic lateral sclerosis (ALS) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Amyotrophic lateral sclerosis (ALS) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Amyotrophic lateral sclerosis (ALS)?
  • Out of all 7MM countries, which country would have the highest prevalent population of Amyotrophic lateral sclerosis (ALS) during the forecast period (2019-2032)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2019-2032)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Amyotrophic lateral sclerosis (ALS) treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Amyotrophic lateral sclerosis (ALS) in the USA, Europe, and Japan?
  • What are the Amyotrophic lateral sclerosis (ALS) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
  • How many companies are developing therapies for the treatment of Amyotrophic lateral sclerosis (ALS)?
  • How many therapies are developed by each company for Amyotrophic lateral sclerosis (ALS) treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for Amyotrophic lateral sclerosis (ALS) treatment?
  • What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Amyotrophic lateral sclerosis (ALS) therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Amyotrophic lateral sclerosis (ALS) and their status?
  • What are the key designations that have been granted for the emerging therapies for Amyotrophic lateral sclerosis (ALS)?
  • What are the global historical and forecasted market of Amyotrophic lateral sclerosis (ALS)?

Reasons to Buy

  • The report will help in developing business strategies by understanding trends shaping and driving the Amyotrophic lateral sclerosis (ALS) market
  • To understand the future market competition in the Amyotrophic lateral sclerosis (ALS) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Amyotrophic lateral sclerosis (ALS) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Amyotrophic lateral sclerosis (ALS) market
  • To understand the future market competition in the Amyotrophic lateral sclerosis (ALS) market
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AB Science
  • Amylyx Pharmaceuticals
  • Apellis Pharmaceuticals
  • Biogen
  • Eledon Pharmaceuticals
  • MediciNova

1 Key Insights2 Report Introduction3 Executive Summary4 Key Events5 SWOT Analysis
6 Amyotrophic Lateral Sclerosis (ALS) Market Overview at a Glance
6.1 Market Share (%) Distribution by Therapies in 2022
6.2 Market Share (%) Distribution by Therapies in 2032
7 Disease Background and Overview
7.1 Introduction
7.2 Types of ALS
7.2.1 Sporadic ALS
7.2.2 Genetic or Familial ALS
7.3 Causes
7.3.1 Genetics
7.3.2 Environmental factors
7.4 Risk factors
7.5 Symptoms
7.6 Clinical Features
7.6.1 Clinical presentation
7.6.2 Amyotrophic lateral sclerosis phenotypes
7.6.3 Subtypes of ALS based on relative UMN versus LMN involvement
7.6.4 Subtypes of motor neuron disease based on the regional distribution of involvement
7.6.5 Subtypes of ALS based on additional frontotemporal involvement
7.7 Pathogenesis
7.7.1 Failure of proteostasis
7.7.2 Disturbed RNA metabolism
7.7.3 Cytoskeletal disturbances and axonal transport defects
7.8 Biomarker
7.9 Prediction of prognosis
7.10 Differential Diagnosis
7.11 Diagnosis
7.11.1 Criteria and requirements for diagnosis
8 Treatment and Management of ALS
8.1 Multidisciplinary Care
8.2 Neuroprotective Treatments
8.2.1 Riluzole
8.2.2 Edaravone
8.2.3 Nuedexta
8.3 Symptomatic Treatments
8.4 Adaptive and Assistive Equipment
8.5 Nutrition
8.6 Respiratory Management
8.7 Secretion Management
8.8 Palliative and End-of-Life Care
9 European Federation of Neurological Societies (EFNS) guidelines on the Clinical Management of ALS (MALS) (2012)10 American Association of Neurology (AAN) Guidelines for Care and Management of patients with ALS (2009)11 Management Algorithm for Respiratory Dysfunction in ALS12 Management guidelines for ALS in Japan, the United States, and Europe.
13 Epidemiology and Patient Population of 7MM
13.1 Key Findings
13.2 Epidemiology Methodology
13.3 Total Prevalent Population of Amyotrophic Lateral Sclerosis (ALS) in the 7MM
13.4 Total Diagnosed Prevalent Population of Amyotrophic Lateral Sclerosis (ALS) in the 7MM
13.5 Assumptions and Rationale
13.6 The United States
13.6.1 Prevalence of Amyotrophic Lateral Sclerosis in the United States
13.6.2 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in the United States
13.6.3 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
13.6.4 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
13.6.5 Type-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
13.6.6 Site of onset of Amyotrophic Lateral Sclerosis in the United States
13.6.7 Age-specific Distribution of Amyotrophic Lateral Sclerosis in the United States
13.7 EU5
13.7.1 Prevalence of of Amyotrophic Lateral Sclerosis (ALS) in EU5
13.7.2 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis (ALS) in EU5
13.7.3 Gender-specific Distribution of Amyotrophic Lateral Sclerosis (ALS) in EU5
13.7.4 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis (ALS) in EU5
13.7.5 Type-specific Distribution of Amyotrophic Lateral Sclerosis (ALS) in EU5
13.8 Japan
13.8.1 Prevalence of Amyotrophic Lateral Sclerosis in Japan
13.8.2 Diagnosed Prevalence of Amyotrophic Lateral Sclerosis in Japan
13.8.3 Gender-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
13.8.4 Mutation-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
13.8.5 Type-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
13.8.6 Site of onset of Amyotrophic Lateral Sclerosis in Japan
13.8.7 Age-specific Distribution of Amyotrophic Lateral Sclerosis in Japan
14 Organizations contributing towards ALS15 Patient Journey
16 Marketed Drugs
16.1 Key Competitor
16.2 Radicava (edaravone injection): Mitsubishi Tanabe Pharma Corporation
16.2.1 Drug Description
16.2.2 Regulatory Milestones
16.2.3 Other Developmental Activities
16.2.4 Current Pipeline Activity
16.2.5 Safety and Efficacy
16.2.6 Product Profile
16.3 Rilutek (Riluzole): Sanofi/Covis
16.3.1 Drug Description
16.3.2 Regulatory Milestones
16.3.3 Other Developmental activities
16.3.4 Safety and Efficacy
16.3.5 Product Profile
16.4 Exservan (Riluzole oral film): Aquestive Therapeutics
16.4.1 Drug Description
16.4.2 Regulatory Milestones
16.4.3 Other Developmental Activities
16.4.4 Safety and Efficacy
16.4.5 Product Profile
16.5 Nuedexta (dextromethorphan hydrobromide/quinidine sulfate): Avanir Pharmaceuticals (a subsidiary of Otsuka America)
16.5.1 Drug Description
16.5.2 Regulatory Milestones
16.5.3 Other Developmental Activities
16.5.4 Safety and Efficacy
16.5.5 Product Profile
16.6 Tiglutik (riluzole): ITF Pharma (a US subsidiary Italfarmaco)
16.6.1 Drug Description
16.6.2 Regulatory Milestones
16.6.3 Other Developmental Activities
16.6.4 Safety and Efficacy
16.6.5 Product Profile
17 Emerging Drugs
17.1 Key Competitors
17.2 Tofersen (BIIB067): Biogen/Ionis
17.2.1 Product Description
17.2.2 Other Developmental Activities
17.2.3 Clinical Development
17.2.4 Safety and Efficacy
17.2.5 Product Profile
17.3 ION363: Ionis Pharmaceuticals
17.3.1 Product Description
17.3.2 Clinical Development
17.3.3 Product Profile
17.4 Ibudilast (MN-166): MediciNova
17.4.1 Product Description
17.4.2 Other Developmental Activities
17.4.3 Clinical Development
17.4.4 Safety and Efficacy
17.4.5 Product Profile
17.5 Masitinib: AB Science
17.5.1 Product Description
17.5.2 Other Developmental Activities
17.5.3 Clinical Development
17.5.4 Safety and Efficacy
17.5.5 Product Profile
17.6 NurOwn (MSC-NTF cells): Brainstorm Cell Therapeutics
17.6.1 Product Description
17.6.2 Other Developmental Activities
17.6.3 Clinical Development
17.6.4 Safety and Efficacy
17.6.5 Product Profile
17.7 AMX0035: Amylyx Pharmaceuticals
17.7.1 Product Description
17.7.2 Other Developmental Activities
17.7.3 Clinical Development
17.7.4 Safety and Efficacy
17.7.5 Product Profile
17.8 EPI-589: DS Pharma/PTC Therapeutics
17.8.1 Product Description
17.8.2 Other Developmental Activities
17.8.3 Clinical Development
17.8.4 Safety and Efficacy
17.8.5 Product Profile
17.9 SLS-005/Trehalose: Seelos Therapeutics
17.9.1 Product Description
17.9.2 Other Developmental Activities
17.9.3 Clinical Development
17.9.4 Product Profile
17.10 Pridopidine: Prilenia Therapeutics
17.10.1 Product Description
17.10.2 Other Developmental Activities
17.10.3 Clinical Development
17.10.4 Safety and Efficacy
17.10.5 Product Profile
17.11 Verdiperstat: Biohaven Pharmaceuticals
17.11.1 Product Description
17.11.2 Other Developmental Activities
17.11.3 Clinical Development
17.11.4 Product Profile
17.12 Zilucoplan: UCB Pharma/Ra Pharmaceuticals
17.12.1 Product Description
17.12.2 Other Development Activities
17.12.3 Clinical Development
17.12.4 Product Profile
17.13 Gold Nanocrystals/CNM-Au8: Clene Nanomedicine Biosciences
17.13.1 Product Description
17.13.2 Other development activity
17.13.3 Clinical Development
17.13.4 Safety and Efficacy
17.13.5 Product Profile
17.14 ANX005: Annexon
17.14.1 Product Description
17.14.2 Other Development activity
17.14.3 Clinical Development
17.14.4 Safety and Efficacy
17.14.5 Product Profile
17.15 AT-1501: Eledon Pharmaceuticals
17.15.1 Product Description
17.15.2 Other Development Activities
17.15.3 Clinical Development
17.15.4 Safety and Efficacy
17.15.5 Product Profile
17.16 AP-101: AL-S Pharma
17.16.1 Product Description
17.16.2 Other Development Activities
17.16.3 Clinical Development
17.16.4 Safety and Efficacy
17.16.5 Product Profile
17.17 Pegcetacoplan (APL-2): Apellis Pharmaceuticals
17.17.1 Product Description
17.17.2 Clinical Development
17.17.3 Product Profile
17.18 Reldesemtiv: Cytokinetics/Astellas Pharma
17.18.1 Product Description
17.18.2 Other Developmental Activities
17.18.3 Clinical Development
17.18.4 Safety and Efficacy
17.18.5 Product Profile
17.19 RNS60: Revalesio Corporation
17.19.1 Product Description
17.19.2 Other Developmental Activities
17.19.3 Clinical Development
17.19.4 Safety and Efficacy
17.19.5 Product Profile
17.20 BIIB078: Biogen
17.20.1 Product Description
17.20.2 Other Developmental Activities
17.20.3 Clinical Development
17.20.4 Product Profile
17.21 PrimeC: NeuroSense Therapeutics
17.21.1 Product Description
17.21.2 Other Developmental Activities
17.21.3 Clinical Development
17.21.4 Safety and Efficacy
17.21.5 Product Profile
18 Amyotrophic Lateral Sclerosis (ALS): 7MM Market Analysis
18.1 Key Findings
18.2 Market Methodology
18.3 Total Market Size of Amyotrophic Lateral Sclerosis in the 7MM
18.4 Market Size of Amyotrophic Lateral Sclerosis by Current Therapies in the 7MM
18.5 Market Size of Amyotrophic Lateral Sclerosis by Emerging Therapies in the 7MM
18.6 Market Outlook
18.7 Attribute Analysis
18.8 Key Market Forecast Assumptions
18.9 United States Market Size
18.9.1 Total Market Size of Amyotrophic Lateral Sclerosis in the United States
18.9.2 Market Size of Amyotrophic Lateral Sclerosis by Current Therapies in the United States
18.9.3 Market Size of Amyotrophic Lateral Sclerosis by Emerging Therapies in the United States
18.10 EU-5 Market Size
18.10.1 Total Market size of Amyotrophic Lateral Sclerosis in Europe
18.10.2 Market Size of Amyotrophic Lateral Sclerosis by Current Therapies in Europe
18.10.3 Market Size of Amyotrophic Lateral Sclerosis by Emerging Therapies in Europe
18.11 Japan
18.11.1 Total Market size of Amyotrophic Lateral Sclerosis in Japan
18.11.2 Market Size of Amyotrophic Lateral Sclerosis by Current Therapies in Japan
18.11.3 Market Size of Amyotrophic Lateral Sclerosis by Emerging Therapies in Japan
19 Market Drivers20 Market Barriers21 Unmet Needs22 Market Access and Reimbursement
23 Appendix
23.1 Bibliography
23.2 Report Methodology
24 Capabilities25 Disclaimer26 About the Publisher
List of Tables
Table 1: Summary of Amyotrophic lateral sclerosis (ALS) Market, and Epidemiology (2019-2032)
Table 2: Key Events
Table 3: List of differential diagnosis and clinical overlap with ALS
Table 4: Summary table of ALS and key differentiating factors with each mimic/variant
Table 5: Diagnostic tests for ALS
Table 6: Revised El Escorial Criteria for ALS
Table 7: Neuroprotective and Symptomatic Treatments for ALS
Table 8: Clinical practice and treatment guidelines for ALS in Japan, the United States, and Europe.
Table 9: Total Prevalent Population of ALS in the 7MM (2019-2032)
Table 10: Total Diagnosed Prevalent Population of ALS in the 7MM (2019-2032)
Table 11: Prevalence of ALS in the US (2019-2032)
Table 12: Diagnosed Prevalence of ALS in the US (2019-2032)
Table 13: Gender-specific Distribution of ALS in the US (2019-2032)
Table 14: Mutation-specific Distribution of ALS in the US (2019-2032)
Table 15: Type-specific Distribution of ALS in the US (2019-2032)
Table 16: Site of onset of ALS in the US (2019-2032)
Table 17: Age-specific Distribution of ALS in the US (2019-2032)
Table 18: Prevalence of ALS in EU5 (2019-2032)
Table 19: Diagnosed Prevalence of ALS in EU5 (2019-2032)
Table 20: Gender-specific Distribution of ALS in EU5 (2019-2032)
Table 21: Mutation-specific Distribution of ALS in EU5 (2019-2032)
Table 22: Type-specific Distribution of ALS in EU5 (2019-2032)
Table 23: Site of onset of ALS in EU5 (2019-2032)
Table 24: Age-specific Distribution of ALS in EU5 (2019-2032)
Table 25: Prevalence of ALS in Japan (2019-2032)
Table 26: Diagnosed Prevalence of ALS in Japan (2019-2032)
Table 27: Gender-specific Distribution of ALS in Japan (2019-2032)
Table 28: Mutation-specific Distribution of ALS in Japan (2019-2032)
Table 29: Type-specific Distribution of ALS in Japan (2019-2032)
Table 30: Site of onset of ALS in Japan (2019-2032)
Table 31: Age-specific Distribution of ALS in Japan (2019-2032)
Table 32: Organizations contributing toward ALS
Table 33: Comparison of marketed drugs
Table 34: Patent Expiration of Radicava
Table 35: Radicava (MT-1186), Clinical Trial Description, 2022
Table 36: Patent Expiration of Exservan
Table 37: Patent Expiration of Nuedexta
Table 38: Patent Expiration of Tiglutik
Table 39: Comparison of emerging drugs under development
Table 40: Tofersen, Clinical Trial Description, 2022
Table 41: ION363, Clinical Trial Description, 2022
Table 42: Ibudilast Clinical Trial Description, 2022
Table 43: Masitinib, Clinical Trial Description, 2022
Table 44: NurOwn, Clinical Trial Description, 2022
Table 45: AMX0035, Clinical Trial Description, 2022
Table 46: EPI-589, Clinical Trial Description, 2022
Table 47: SLS-005, Clinical Trial Description, 2022
Table 48: Pridopidine, Clinical Trial Description, 2022
Table 49: Verdiperstat, Clinical Trial Description, 2022
Table 50: Zilucoplan, Clinical Trial Description, 2022
Table 51: CNM-Au8, Clinical Trial Description, 2022
Table 52: CNM-Au8, Clinical Trial Description, 2022
Table 53: AT-1501, Clinical Trial Description, 2022
Table 54: AP-101, Clinical Trial Description, 2022
Table 55: Pegcetacoplan, Clinical Trial Description, 2022
Table 56: Reldesemtiv, Clinical Trial Description, 2022
Table 57: RNS60, Clinical Trial Description, 2022
Table 58: BIIB078, Clinical Trial Description, 2022
Table 59: PrimeC, Clinical Trial Description, 2022
Table 60: Market Size of ALS in the 7MM in USD Million (2019-2032)
Table 61: Market Size of ALS by Current Therapies in the 7MM, in USD Million (2019-2032)
Table 62: Market Size of ALS by Emerging Therapies in the 7MM, in USD Million (2019-2032)
Table 63: Attribute analysis of Emerging drugs
Table 64: Key Market Forecast Assumptions for Tofersen/BIIB067
Table 65: Key Market Forecast Assumptions for Ibudilast
Table 66: Key Market Forecast Assumptions for Masitinib
Table 67: Key Market Forecast Assumptions for NurOwn
Table 68: Key Market Forecast Assumptions for AMX0035
Table 69: Key Market Forecast Assumptions for EPI-589
Table 70: Key Market Forecast Assumptions for ANX005
Table 71: Key Market Forecast Assumptions for AT-1501
Table 72: Key Market Forecast Assumptions for AP-101
Table 73: Key Market Forecast Assumptions for BIIB078
Table 74: Key Market Forecast Assumptions for ION363
Table 75: Key Market Forecast Assumptions for PrimeC
Table 76: Key Market Forecast Assumptions for Pegcetacoplan
Table 77: Key Market Forecast Assumptions for Zilucoplan
Table 78: Key Market Forecast Assumptions for CNM-Au8
Table 79: Key Market Forecast Assumptions for Pridopidine
Table 80: Key Market Forecast Assumptions for SLS-005
Table 81: Key Market Forecast Assumptions for Verdiperstat
Table 82: Key Market Forecast Assumptions for RNS60
Table 83: Key Market Forecast Assumptions for Reldesemtiv
Table 84: Market Size of ALS in the US, USD Million (2019-2032)
Table 85: Market Size of ALS by Current Therapies in the US, in USD Million (2019-2032)
Table 86: Market Size of ALS by Emerging Therapies in the US, in USD Million (2019-2032)
Table 87: EU5 Market Size of ALS in USD Million (2019-2032)
Table 88: EU5 Market Size of ALS by Current Therapies in USD Million (2019-2032)
Table 89: EU5 Market Size of ALS by Emerging Therapies in USD Million (2019-2032)
Table 90: Market Size of ALS by Current Therapies in Japan, in USD Million (2019-2032)
Table 91:Market Size of ALS by Emerging Therapies in the US, in USD Million (2019-2032)
Table 92:Market Size of ALS by Emerging Therapies in the US, in USD Million (2019-2032)
List of Figures
Figure 1: Phenotypic presentations of ALS.
Figure 2: Clustering of ALS genes in pathogenic pathways.
Figure 3: Flowchart for the management of respiratory dysfunction in ALS/ motor neuron disease (MND)
Figure 4: Total Prevalent Population of ALS in the 7MM (2019-2032)
Figure 5: Total Diagnosed Prevalent Population of ALS in the 7MM (2019-2032)
Figure 6: Prevalence of ALS in the US (2019-2032)
Figure 7: Diagnosed Prevalence of ALS in the US (2019-2032)
Figure 8: Gender-specific Distribution of ALS in the US (2019-2032)
Figure 9: Mutation-specific Distribution of ALS in the US (2019-2032)
Figure 10: Type-specific Distribution of ALS in the US (2019-2032)
Figure 11: Site of onset of ALS in the US (2019-2032)
Figure 12: Age-specific Distribution of ALS in the US (2019-2032)
Figure 13: Prevalence of ALS in EU5 (2019-2032)
Figure 14: Diagnosed Prevalence of ALS in EU5 (2019-2032)
Figure 15: Gender-specific Distribution of ALS in EU5 (2019-2032)
Figure 16: Mutation-specific Distribution of ALS in EU5 (2019-2032)
Figure 17: Type-specific Distribution of ALS in EU5 (2019-2032)
Figure 18: Site of onset of ALS in EU5 (2019-2032)
Figure 19: Age-specific Distribution of ALS in EU5 (2019-2032)
Figure 20: Prevalence of ALS in Japan (2019-2032)
Figure 21: Diagnosed Prevalence of ALS in Japan (2019-2032)
Figure 22: Gender-specific Distribution of ALS in Japan (2019-2032)
Figure 23: Mutation-specific Distribution of ALS in Japan (2019-2032)
Figure 24: Type-specific Distribution of ALS in Japan (2019-2032)
Figure 25: Site of onset of ALS in Japan (2019-2032)
Figure 26: Age-specific Distribution of ALS in Japan (2019-2032)
Figure 27: Market Size of ALS in the 7MM in USD Million (2019-2032)
Figure 28: Market Size of ALS by Current Therapies in the 7MM, in USD Million (2019-2032)
Figure 29: Market Size of ALS by Emerging Therapies in the 7MM, in USD Million (2019-2032)
Figure 30: Market Size of ALS in the US, USD Millions (2019-2032)
Figure 31: Market Size of ALS by Current Therapies in the US, USD Million (2019-2032)
Figure 32: Market Size of ALS by Emerging Therapies in the US, USD Million (2019-2032)
Figure 33: Market Size of ALS in EU5, USD Million (2019-2032)
Figure 34: EU5 Market Size of ALS by Current Therapies in USD Million (2019-2032)
Figure 35: EU5 Market Size of ALS by Emerging Therapies in USD Million (2019-2032)
Figure 36: Market Size of ALS in Japan, USD Million (2019-2032)
Figure 37: Japan Market Size of ALS by Current Therapies, USD Million (2019-2032)
Figure 38:Japan Market Size of ALS by Emerging Therapies, USD Million (2019-2032)
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Mitsubishi Tanabe Pharma Corporation
  • Sanofi/Covis
  • Aquestive Therapeutics
  • Avanir Pharmaceuticals (a subsidiary of Otsuka America)
  • Biogen
  • Ionis Pharmaceuticals
  • MediciNova
  • AB Science
  • Brainstorm Cell Therapeutics
  • Amylyx Pharmaceuticals
  • DS Pharma/PTC Therapeutics
  • Seelos Therapeutics
  • Prilenia Therapeutics
  • Biohaven Pharmaceuticals
  • UCB Pharma/Ra Pharmaceuticals
  • Clene Nanomedicine Biosciences
  • Annexon
  • Eledon Pharmaceuticals
  • AL-S Pharma
  • Apellis Pharmaceuticals
  • Cytokinetics/Astellas Pharma
  • Revalesio Corporation
  • NeuroSense Therapeutics
Note: Product cover images may vary from those shown